Azhar M. Awan to Prostatic Neoplasms
This is a "connection" page, showing publications Azhar M. Awan has written about Prostatic Neoplasms.
Connection Strength
0.303
-
Racial differences in prostate-specific antigen levels in patients with local-regional prostate cancer. Cancer Epidemiol Biomarkers Prev. 1992 Nov-Dec; 1(7):541-5.
Score: 0.049
-
Radioimmunoscintigraphy for postprostatectomy radiotherapy: analysis of toxicity and biochemical control. J Nucl Med. 2004 Aug; 45(8):1315-22.
Score: 0.028
-
Analysis of prostate-specific antigen rebound interval in patients with prostate cancer receiving hormonal therapy and external-beam radiation therapy. Clin Prostate Cancer. 2004 Jun; 3(1):43-8.
Score: 0.028
-
Influence of radioimmunoscintigraphy on postprostatectomy radiotherapy treatment decision making. J Nucl Med. 2004 Apr; 45(4):571-8.
Score: 0.027
-
Evolution of toxicity after conformal radiotherapy for prostate cancer. Prostate Cancer Prostatic Dis. 2002; 5(4):296-303.
Score: 0.023
-
Changing face and different countenances of prostate cancer: racial and geographic differences in prostate-specific antigen (PSA), stage, and grade trends in the PSA era. Int J Cancer. 2001 Dec 20; 96(6):363-71.
Score: 0.023
-
Equivalent racial outcome after conformal radiotherapy for prostate cancer: a single departmental experience. J Clin Oncol. 2001 Jan 01; 19(1):54-61.
Score: 0.022
-
Television and news print media are effective in recruiting potential participants in a prostate cancer chemoprevention trial. Int J Cancer. 2000 Oct 20; 90(5):302-4.
Score: 0.021
-
PSA-based outcome analysis after radiation therapy for prostate cancer: a new definition of biochemical failure after intervention. Urology. 1999 Oct; 54(4):700-5.
Score: 0.020
-
Potency preservation following conformal radiotherapy for localized prostate cancer: impact of neoadjuvant androgen blockade, treatment technique, and patient-related factors. Cancer J Sci Am. 1999 Jul-Aug; 5(4):230-6.
Score: 0.020
-
Potency probability following conformal megavoltage radiotherapy using conventional doses for localized prostate cancer. Int J Radiat Oncol Biol Phys. 1997 Feb 01; 37(3):551-7.
Score: 0.017
-
Effect of subcutaneous recombinant human erythropoietin in cancer patients receiving radiotherapy: preliminary results of a randomized, open-labeled, phase II trial. Int J Radiat Oncol Biol Phys. 1993 Jul 15; 26(4):721-9.
Score: 0.013
-
Acute toxicity during external-beam radiotherapy for localized prostate cancer: comparison of different techniques. Int J Radiat Oncol Biol Phys. 1993 Jan 15; 25(2):359-71.
Score: 0.013